Effects of profit-reducing policies on firm survival, financial performance, and new drug introductions in the research-based pharmaceutical industry

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 329-351

  Filson, Darren ^a   Masia, Neal ^b  

^a CLAREMONT GRADUATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548337208     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1344     Document Type: Article

References (21)

1. Bartelsman EJ, Gray W. 1996. The NBER manufacturing productivity database. NBER Technical Working Paper 205.
2. Berk JB, Green RC, Naik V. 2004. Valuation and return dynamics of new ventures. Review of Financial Studies 17(1): 1-35.
3. Brealey RA, Myers SC. 2003. Principles of Corporate Finance. McGraw-Hill/Irwin: Boston.
4. Cochrane JH. 2001. Asset Pricing. Princeton University Press: Princeton.
5. Cockburn IM, Henderson RM. 2001. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of Health Economics 20: 1033-1057.
6. Danzon PM, Ketcham JD. 2004. Reference pricing of pharmaceuticals for medicare: evidence from Germany, The Netherlands, and New Zealand, In DM Cutler and AM Garber (eds.) Frontiers in Health Policy Research 7 (National Bureau of Economic Research and MIT Press): 1-54.
7. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
8. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. 1991, Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10: 107-142.
9. Filson D, Gretz RT. 2004. Strategic innovation and technology adoption in an evolving industry. Journal of Monetary Economics 51(1): 89-121.
10. Filson D, Morales R. 2006. Equity links and information acquisition in biotechnology alliances. Journal of Economic Behavior & Organization, 59(1): 1-28.
11. Gilbert J, Henske P, Singh A. 2003. Rebuilding big pharma's business model. In Vivo The Business & Medicine Report 21(10). Available at windhover.com.
12. Grabowski H, Vernon JM. 1987. Pioneers, imitators, and generics - a simulation model of Schumpeterian competition. Quarterly Journal of Economics 102(3): 491-525.
13. Grabowski H, Vernon J, DiMasi JA. 2002. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20(Suppl. 3): 11-29.
14. Henderson R. Cockburn I. 1996. Scale, scope, and spillovers: the determinants of research productivity in drug discovery, RAND Journal of Economics 27(1): 32-59.
15. Hsu JC, Schwartz ES. 2003. A model of R&D valuation and the design of research incentives. Anderson Graduate School of Management Working Paper, University of California, Los Angeles.
16. Hughes JW, Moore MJ, Snyder EA. 2002. 'Napsterizing' pharmaceuticals: access, innovation, and consumer welfare. National Bureau of Economic Research Working Paper #9229.
17. Lichtenberg F, Waldfogel J. 2003. Does misery love company? NBER Working Paper 9750.
18. Myers SC, Howe CD. 1997. A life-cycle model of pharmaceutical R&D. Massachusetts Institute of Technology Working Paper.
19. PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2003/2004. 2003. PAREXEL: Waltham, MA.
20. Schwartz ES. 2004. Patents and R&D as real options. Economic Notes 33(1): 23-54.
21. Thomas LG. 1990. Regulation and firm size: FDA impacts on innovation. RAND Journal of Economics 21(4): 497-517.